Article citationsMore>>

Miguel, A., Herrero, M.J., Sendra, L., Botella, R., Algás, R., Sánchez, M. and Alino, S.F. (2013) Comparative Antitumor Effect among GM-CSF, IL-12 and GM-CSF+IL-12 Genetically Modified Tumor Cell Vaccines. Cancer Gene Therapy, 20, 576-578.
https://doi.org/10.1038/cgt.2013.54

has been cited by the following article:

• TITLE: The Effect of Granulocyte Macrophage-Colony Stimulating Factor upon the Induction of Peripheral Blood Dendritic and Natural Killer Cells When Given Simultaneously with a Slow Continuous Doxorubicin Infusion

  AUTHORS: Arthur J. Weiss, Irwin L. Stoloff, Antonio C. Simoes

  KEYWORDS: Doxorubicin Infusion Dendritic, Killer Cells

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.7, July 18, 2017

  ABSTRACT: It has been demonstrated that it is safe to give Gm-Csf, together with Doxorubicin, by continuous intravenous infusion, thereby substantially increasing the amount of Doxorubicin administered to the average patient, and assuring that each patient receives an individually-determined safe and maximal amount of drug. It is known that Gm-Csf is a potent inducer of components that are major factors in an immunologic attack upon neoplasms. For that reason, we thought it would be worth evaluating in 4 patients’ surface markers of dendritic precursor cells, dendritic cells [DC], and natural killer [NK] cells during the infusion. While there was substantial variation in individual responses, all 4 patients receiving Gm-Csf developed persistent marked increases in cells with each of these markers. The significance of these findings will be discussed.